Genelux Past Earnings Performance
Past criteria checks 0/6
Genelux's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 54.8% per year.
Key information
-14.6%
Earnings growth rate
15.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 54.8% |
| Return on equity | -145.3% |
| Net Margin | -16,645.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Genelux makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -28 | 12 | 13 |
| 30 Sep 23 | 0 | -25 | 9 | 11 |
| 30 Jun 23 | 11 | -15 | 9 | 11 |
| 31 Mar 23 | 11 | -12 | 8 | 10 |
| 31 Dec 22 | 11 | -5 | 5 | 9 |
| 30 Sep 22 | 11 | -5 | 6 | 8 |
| 30 Jun 22 | 0 | -13 | 5 | 7 |
| 31 Mar 22 | 0 | -17 | 8 | 7 |
| 31 Dec 21 | 0 | -16 | 8 | 6 |
| 31 Mar 21 | 0 | -13 | 5 | 6 |
| 31 Dec 20 | 0 | -14 | 6 | 6 |
Quality Earnings: GNLX is currently unprofitable.
Growing Profit Margin: GNLX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GNLX is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare GNLX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GNLX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: GNLX has a negative Return on Equity (-145.31%), as it is currently unprofitable.